secwatch / observer
8-K filed April 2, 2024, 7:59 PM ET ticker BKYI CIK 0001019034
earnings confidence high sentiment negative materiality 0.70

BIO-key reports preliminary 2023 revenue up 29% to $9.1M, net loss $(6.2M) after $2.8M inventory reserve

BIO KEY INTERNATIONAL INC

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO KEY INTERNATIONAL INC reported fourth quarter ended December 31, 2023 results: net income $(4.1M), EPS $(5.54) per share.

Period
fourth quarter ended December 31, 2023
Net income
$(4.1M)
EPS
$(5.54) per share
Result
preliminary results
Exact text from the filing
Likewise, in Q4’23 BIO-key reduced its net loss more than 40% to $(4.1M), or $(5.54) per share, from $(6.7M), or $(14.58) per share in 2023.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO KEY INTERNATIONAL INC reported year ended December 31, 2023 results: revenue $9.1M, net income $(6.2M), EPS $(11.45) per share.

Period
year ended December 31, 2023
Revenue
$9.1M
Net income
$(6.2M)
EPS
$(11.45) per share
Result
preliminary results
Exact text from the filing
Exhibit 99.1 Identity and Access Management Software Provider BIO-key Preliminary 2023 Results: Operating Loss Trimmed Approx. $3.5M on Approx. 29% Revenue Growth to $9.1M; Investor Call Tomorrow at 10am ET Holmdel, NJ – April 1, 2024 – BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and
View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO KEY INTERNATIONAL INC filing history →

Source: SEC EDGAR
accession 0001437749-24-010505
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.